NCT03014635View on ClinicalTrials.gov

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

PHASE3CompletedINTERVENTIONAL

Enrollment

306

Participants

Timeline

Start Date

December 5, 2016

Primary Completion Date

November 3, 2017

Study Completion Date

November 3, 2017

Conditions

Glabellar Frown Lines

Interventions

BIOLOGICAL

Botulinum Toxins, Type A

Intramuscular injection

BIOLOGICAL

Placebos

Intramuscular injection

Trial Locations (14)

11795

West Islip

20037

Washington D.C.

27262

High Point

60563

Naperville

68144

Omaha

70124

New Orleans

90069

Los Angeles

92024

Encinitas

99202

Spokane

V5Z 4E1

Vancouver

L7N 3N2

Burlington

M5R 3N8

Toronto

L4L 8E2

Woodbridge

H3Z 1B7

Montreal

All Listed Sponsors

lead

Revance Therapeutics, Inc.

INDUSTRY

NCT03014635 - Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines | Biotech Hunter | Biotech Hunter